Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 38

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 38
---
16 of the Exchange Act and related rules with respect to their purchases
and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on the ASX and
expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial statements
with the SEC as frequently or as promptly as U. S. public companies that file quarterly reports on Form 10-Q.

Any loss of our foreign private issuer status
in the future could result in significant additional cost.

While we currently qualify
as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer’s
most recently completed second fiscal quarter. In the future, we would lose our foreign private issuer status if we to fail to meet the
requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if 50% or more
of our securities are held by U. S. residents and more than 50% of our senior management or directors are residents or citizens of the
United States, we could lose our foreign private issuer status.

The regulatory and compliance
costs to us under U. S. securities laws as a U. S. domestic issuer could be significantly more than costs we incur as a foreign private
issuer. If we were to cease to be a foreign private issuer, then we would be required to file periodic reports and registration statements
on U. S. domestic issuer forms with the SEC, which forms are more detailed and extensive in certain respects than the forms available to
a foreign private issuer. We would be required to prepare our financial statements in accordance with U. S. GAAP rather than IFRS. Such
conversion of our financial statements to U. S. GAAP would involve significant time and cost. In addition, we could lose our ability to
rely upon exemptions from certain corporate governance requirements on U. S. stock exchanges that are available to foreign private issuers
such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies.

U. S. investors may have difficulty enforcing
civil liabilities against our company, our directors or members of senior management and the experts named in this Annual Report.

Certain members of our senior
management and board of directors named in this Annual Report are non-residents of the United States, and a substantial portion of the
assets of such persons are located outside the United States. As